Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$170B | 18.5x | -1.31 | HK$55.10 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$145.80B | -0.2x | -1.39 | HK$104.70 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$69.86B | 22.9x | -0.68 | HK$17.02 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12% Upside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$54.62B | -74.9x | 0.51 | HK$60.85 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$51.87B | 55.1x | -0.88 | HK$32.25 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.7% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$48.04B | 26.4x | 1.13 | HK$13.72 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$39.80B | -188x | -2.94 | HK$178.60 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.5% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$20.87B | -14.8x | -3.23 | HK$9.74 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$20.28B | -20.6x | HK$54.70 | 10.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$14.76B | -5.5x | 0.52 | HK$14.76 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.6% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.31B | -34.3x | -0.56 | HK$42.95 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.4% Upside | Upgrade to Pro+ | |
Lepu Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.78B | -49.2x | -0.77 | HK$2.98 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lepu Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.78B | -49.2x | -0.77 | HK$2.98 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.59B | -17,410x | HK$8.76 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.2% Downside | Upgrade to Pro+ | ||
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.45B | -28.9x | -0.86 | HK$5.93 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$8.98B | -13.4x | 0.06 | HK$32.60 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.62B | -3.5x | -0.25 | HK$8.42 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.94B | -6.4x | -0.47 | HK$8.23 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.36B | 40.4x | -1.09 | HK$1.66 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -40% Downside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.36B | -11.4x | -0.24 | HK$8.42 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.33B | -10.7x | -37.27 | HK$3.46 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.7% Downside | Upgrade to Pro+ | |
CStone | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.94B | -15.8x | -0.24 | HK$2.30 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.71B | -180x | -1.62 | HK$4.34 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.05B | -5.4x | -7.97 | HK$5.03 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.64B | -11x | HK$7.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.50B | -5.2x | 0.14 | HK$1.53 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tot Biopharm Intl | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.24B | 142.2x | 1.1 | HK$1.60 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.5% Upside | Upgrade to Pro+ | |
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.20B | -4.6x | 1.01 | HK$2.34 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.15B | -5.9x | 0.79 | HK$0.28 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.02B | -3x | -0.19 | HK$1.29 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |